PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5.
| Autor: | CARLO‐STELLA, C., Linhares, Y., Gandhi, M. D., Chung, M., Adamis, H., Ungar, D., Hamadani, M. |
|---|---|
| Zdroj: | Hematological Oncology; Jun2021 Supplement S2, Vol. 39, p1-2, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Plný text